Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that Kineta’s management team has been invited to participate at H.C. Wainwright Bioconnect Virtual Conference that is being held on January 10-13, 2022.
SEATTLE, Jan. 11, 2022 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Kineta’s management team has been invited to participate at H.C. Wainwright Bioconnect Virtual Conference that is being held on January 10-13, 2022. Shawn Iadonato, Kineta Chief Executive Officer, will present a corporate overview that will be available on-demand from January 10-13 to attendees registering via H.C. Wainwright at https://hcwevents.com/bioconnect/.
Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives. We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact:
Jacques Bouchy
327354@email4pr.com
(206) 378-0400
View original content to download multimedia:https://www.prnewswire.com/news-releases/kineta-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301458284.html
SOURCE Kineta, Inc.
